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Abstract
The increased prevalence of expanded carrier screening (ECS) has made it possible for
individuals to receive incidental diagnoses of genetic conditions through prenatal or
preconception screening that was originally intended to assess risk for genetic conditions in
future offspring. The inclusion of genetic conditions with variable expressivity and late-onset
phenotypes, such as certain lysosomal storage disorders, have increased the likelihood that this
type of screening will result in an incidental diagnosis. Four participants from the lysosomal
storage disorders program at NYU Langone Health were interviewed to elicit their psychological
reaction to incidental diagnoses of Gaucher Disease Type 1, Fabry Disease and Late-onset
Pompe Disease. Relevant themes include the quality of explanation of the diagnosed genetic
condition, availability of support from medical providers, and consequences of the condition on
aspects of daily living. Overall, participants believed that expanded carrier screening gave
important information and recommended that providers responsible for ordering ECS or
explaining results offer an appropriate level of education and compassion to their patients. Their
responses reveal room for improvement in pre-test counseling, disclosure of incidental
diagnoses, patient education during post-test counseling and referral services within the role of
the genetic provider.
KEYWORDS: expanded carrier screening, incidental diagnosis, lysosomal storage
disorder, attitudes, patient perspective, psychosocial, adult-onset, late-onset, asymptomatic
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Introduction
Panel tests that analyze many genes at once have changed the terrain of carrier screening,
increasing the efficiency and affordability of genetic testing and expanding the options available
to patients. Carrier screening assists individuals and couples in determining their risk for having
a pregnancy affected by an autosomal recessive or X-linked condition, and has traditionally been
offered according to individuals’ ethnicity or family history as recommended by professional
societies such as the American College of Obstetricians and Gynecologists (The American
College of Obstetricians and Gynecologists, 2017). In recent years, expanded carrier screening
(ECS) has become an option to assess genetic risks. Unlike traditional screening, it is offered
regardless of ethnicity or family history and allows patients to uncover their reproductive risk for
hundreds of conditions simultaneously.
The breadth of conditions tested by expanded carrier screening poses both challenges and
benefits to patients and providers. One of these challenges is the risk of an incidental diagnosis,
where an individual who receives carrier screening finds that he or she has a genetic diagnosis of
one of the conditions included on a carrier screening panel. Because many ECS panels now
include conditions for which there can be medical consequences to carriers, these incidental
diagnoses are becoming more common (Wong, Lazarin, & Haque, 2016) and pose unique
obstacles for pre- and post-test counseling. A significant number of disorders that are included
on ECS panels have reduced penetrance, variable expressivity and late-onset phenotypes, and
providers often have difficulty in addressing these phenotypic nuances during pre-test counseling
(Janssens et al., 2017). Not all providers who offer carrier screening are genetics professionals,
and some studies have shown that providers can have insufficient knowledge about the genetic
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implications of carrier status, appropriate referrals after a positive screening results, and
guidelines regarding carrier screening (Qureshi, 2006; Darcy et al., 2012).

Current state of ECS, risks and benefits
There is currently much variation in the way laboratories approach carrier screening in
terms of the method of testing, number of conditions included, types of inheritance associated
with the conditions, and types of result reporting. In a survey of 16 expanded carrier screening
providers in 2018, Chokoshvilli, Vears and Borry found that there was great variability in the
number of genetic conditions included, which ranged from dozens to over 1000. Laboratories
used different types of sequencing even when testing for the same disease; while most of them
provided targeted genotyping for screening cystic fibrosis, some offered complete gene
sequencing and copy number variation (CNV) analysis. Among the laboratories who offered
targeted sequencing, the number of allele positions analyzed ranged from 28 variants to over
600, and laboratories often used a combination of these testing strategies in their analysis. In
addition to autosomal recessive diseases, some providers offer screening for X-linked and
autosomal dominant conditions, such as Fragile X Syndrome and familial hypercholesterolemia,
which increase the probability of returning positive results that have health implications for the
individual being screened. Some laboratories reported only pathogenic or likely pathogenic
variants while others provided information on variants of uncertain significance. Even though all
laboratories included in the study provided screening for cystic fibrosis, spinal muscular atrophy
and maple syrup urine disease type 1B, there were no consistent criteria by which other
conditions were selected for inclusion in these panels (Chokoshvilli, Vears & Borry, 2018).
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ECS poses both advantages and limitations to patients. Testing for a larger number of
conditions independent of ethnicity can reveal positive carrier status for conditions that are not
anticipated based on an individual’s family history or ethnic background, providing additional
benefit to the patient in making family planning decisions for conditions they were otherwise
unaware of. In a study of 23,453 individuals across ethnicities, 24% were found to be carriers for
at least one of 108 genetic disorders (Lazarin et al., 2013). Another study of 4,232 infertility
patients who underwent ECS through a single panel that screened for 100 conditions showed that
29.4% carried at least one condition, as opposed to 8.5% that would have been identified if
carrier screening were offered only based on ethnicity (Peyser et al., 2019). Current sequencing
techniques allow for multiple analyses to be performed on the same sample without a
proportional increase in sequencing costs, allowing individuals to make informed reproductive
decisions using a broader pool of genetic information. The increased likelihood of screening
positive on ECS panels can help improve the public’s knowledge of carrier status and possibly
decrease stigma for such a phenomenon (Kraft et al., 2019).
The breadth and complexity of ECS can make it challenging for patients to understand
the methodology behind ECS and the implications of its results. For example, 30% of a sample
of Dutch patients surveyed about their opinions regarding ECS were under the impression that a
positive carrier status for a recessive condition signifies that they would experience symptoms of
the condition, even though this is not the case for carriers of most diseases. Additionally,
participants often misunderstood the nature of autosomal recessive conditions, indicating that
they did not feel a need to undergo carrier screening when they had no family history of any
genetic condition (Nijmeijer et al., 2019). Interviews of women receiving expanded carrier
screening as a part of their prenatal care revealed confusion between ECS and other types of
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prenatal testing, such as screening for Down Syndrome (Rothwell et al., 2017). Another
complication of carrier screening in general is that it is often offered by non-genetics
professionals such as obstetricians, who are not necessarily familiar with its benefits and
limitations. An online survey of 156 obstetricians on their knowledge about screening for cystic
fibrosis demonstrated that although most of them knew about screening guidelines, 17% did not
interpret results correctly and 43% could not provide statistics for carrier frequency, screening
sensitivity and residual risk (Darcy et al., 2012).

Incidental diagnosis through ECS
Within the broad range of conditions that are included on ECS, it is increasingly likely
for individuals undergoing ECS to receive an incidental diagnosis. In a retrospective study of
23,453 participants who underwent ECS via genotyping, 78 individuals tested homozygous or
compound heterozygous for recessive conditions that have variable expressivity or late-onset
phenotypes, prominent among them hemoglobinopathies, cystic fibrosis and Gaucher Disease
(Haque et al., 2016). The fact that many individuals are asymptomatic at the time of incidental
diagnosis complicates patient education, as does the need to balance reproductive risks with adult
health management (Lazarin et al., 2013). There is concern that asymptomatic individuals
incidentally diagnosed through ECS may face undue psychological burden and seek unnecessary
medical care if they never manifest symptoms of a low-penetrance or variably expressed
condition. The need for diagnostic testing to confirm ECS results adds further inconvenience and
burden to the patient experience (Wienke et al., 2014).
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Expert recommendation regarding ECS
Given the discrepancy in curation of ECS panels, the American Association of Obstetrics
and Gynecology (ACOG) has developed recommendations for designing such panels in a way
that encourages clinical utility. The ACOG committee proposed a carrier frequency of at least
1/100 for conditions to be tested in ECS panels, and designated a number of additional criteria to
be met: a “well-defined phenotype” which has been extensively studied in literature; significant
negative impact on cognitive or physical function that decreases life quality; the availability of
medical or surgical procedures used to treat the condition; ability for the condition to be
diagnosed prenatally in order for the mother to take preventative or ameliorative action; and
early onset. The committee discourages the inclusion of diseases that have late-onset phenotypes
and emphasizes the continued importance of assessing individuals’ reproductive genetic risk
based on personal and family history (The American College of Obstetricians and Gynecologists,
2017).
Opinions differ as to the effectiveness of these recommendations in producing clinically
useful results. Ben-Shachar et al. argue that the 1/100 carrier frequency is too conservative and
would prevent a significant portion of individuals undergoing ECS from discovering their carrier
status. It maintains that the increased yield of ECS outweighs the burden it places on public
health costs (Ben-Shachar et al., 2019). Lazarin et al. also remark that while carrier screening
guidelines recommended by organizations like ACOG and the American College of Medical
Genetics and Genomics (ACMG) are effective at discovering carriers in certain ethnic groups,
they still miss the majority of carriers for most genetic conditions (Lazarin et al., 2013). On the
other hand, Grody, Cutting and Watson assert that ACOG recommendations should be observed
because they adequately enforce carrier screening test quality. Using cystic fibrosis as an
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example, the authors argue that expanding the number of loci tested in CFTR beyond the 25 that
were strongly recommended by ACOG and ACMG led to high false positive rates, low positive
predictive value, and low marginal returns on additional costs used for sequencing more loci.
They state that competition between laboratories to include more loci becomes arbitrary and
drives out smaller laboratories who offer good quality testing but a smaller number of loci
(Grody, Cutting, & Watson, 2007).

Attitudes toward ECS
Few studies have investigated patient attitudes towards expanded carrier screening, but
some investigations reveal the psychosocial experience of patients who have undergone
traditional carrier screening. Overall, patients viewed carrier screening positively. A majority of
patients reported feeling relief or satisfaction after finding out their negative carrier status, and
many did not change their health behavior or health coverage as a result of carrier screening.
Most patients experienced no or low levels of anxiety throughout the screening process, and
some individuals appreciated the convenience of screening for multiple conditions with a single
blood draw (Kraft et al., 2018). Negative reactions to carrier screening included feeling
psychological distress during sequential screening of individuals’ partners after one partner was
discovered to be a carrier for a particular condition. In a structured interview of 10 women who
underwent carrier screening in Australia, many participants stated that they did not expect to
receive a positive result, and experienced anxiety while waiting for their partners’ results.
Because most of these participants were already pregnant, the implications of positive results
were more dire as they signaled the possibility of termination. Most of the participants
recognized that carrier screening was voluntary and did not feel pressured to undergo it, although
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many participants mentioned that they agreed to the screening out of convenience, as it did not
require another blood draw in addition to the one needed for their other laboratory tests (Beard et
al., 2016).
Providers also hold different opinions in regard to the benefits, limitations and best
practices regarding expanded carrier screening. In a sample of 16 European geneticists, the
majority agreed on the way expanded carrier screening should be presented to patients: ideally it
would be in a preconception setting to maximize individuals’ capacity for reproductive decision
making and offered in a way that does not coerce patients to undergo testing. They also agreed
on the importance of appropriate post-test counseling, emphasizing that couples should have
access to a detailed explanation of the relevant genetic condition, consultation with a specialist of
the condition, and opportunities to meet with individuals who have the condition. In terms of
pre-test counseling, providers disagreed on the level of detail that should be offered to patients
about the characteristics of the conditions that would be screened. Some preferred a generalized
consent with no mention of specific conditions while others preferred to categorize conditions
based on characteristics like severity. The geneticists also disagreed on whether expanded carrier
screening should be offered exclusively to couples or include individuals as well. Some
geneticists oppose offering expanded carrier screening to individuals for the purpose of
excluding future partners with whom they can have a high-risk pregnancy, while others approve
of using ECS for partner selection. Several participants approved of ECS due to the fact that
many individuals with family histories of genetic conditions seek carrier screening to rule out
their own risk (Janssens et al., 2017).
Cho, et al. also investigated the opinions of several focus groups of genetics professionals
on ECS, and some participants highlighted further challenges to expanded carrier screening.
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Because many of the conditions included on ECS are rarer than the ones included on traditional
screening, some participants noted that obstetric providers who are familiar with traditional
screening may not be prepared for positive results that may be returned for rare genetic
conditions, and that positive results may warrant referral to a geneticist or genetic counselor for
further evaluation. Other participants emphasized the importance of clarifying limitations of ECS
during pre-test counseling, including the fact that ECS does not screen for aneuploidies, and that
a negative ECS result does not necessarily mean a risk-free pregnancy or a complete ruling out
of carrier status for genetic conditions included in the testing (Cho et. al., 2013).

Lysosomal Storage Disorders
Lysosomal storage disorders (LSDs) are a group of about 50 disorders, some of which are
commonly screened for on expanded carrier screening panels. In general, LSDs are characterized
by a build-up of substrate in the lysosomes; organelles that aid in the digestive system of the cell
(Germain, 2010). Often, LSDs are caused by enzymatic deficiency or deficiency of other types
of proteins that help enzymes digest their target substrates. All together these disorders have a
prevalence of less than 1 in 7000 live births (Wasserstein et al., 2019). Usually, early-onset
forms are most severe with rapid onset of disease, and late-onset forms have milder, more slowly
progressive symptoms (Freeze, Kinoshita, & Schnaar, 2017). An increasing number of patients
with mild forms of lysosomal storage disorders are being diagnosed via expanded carrier
screening. Three LSDs that have been incidentally diagnosed by carrier screening are outlined in
more detail.
Gaucher disease is an autosomal recessive LSD caused by two pathogenic variants in the
GBA gene which results in deficiency of the enzyme β-glucocerebrosidase, and accumulation of
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the glycolipid, glucocerebroside, within the lysosome (Freeze, Kinoshita, & Schnaar, 2017). This
disorder takes three forms which are differentiated by a severity and impact on the central
nervous system. In general, all types of Gaucher disease have some degree of bone disease,
anemia, platelet deficiency and hepatosplenomegaly. Gaucher disease type 1 (GD1) is more
common and is characterized by the lack of progressive neurodegenerative disease and central
nervous system disease.
GD1 can be diagnosed by assessing the enzyme activity level of β-glucocerebrosidase in
leukocytes or through molecular genetic testing for pathogenic variants in the GBA gene. GD1
has a frequency of approximately 1 in 57,000 births making it the most common LSD. It is
shown to be more frequent in Ashkenazi Jewish (1 in 855), Spanish, Portuguese, Swedish,
Greek, and Albanian populations due to a founder effect. Observed prevalence of patients with
GD1 is much lower than expected based on carrier frequency, suggesting that this is a lowpenetrance disease (Zuckerman et al., 2007). Notably, homozygosity or compound
heterozygosity for the common variants N370S and R496H often produce mild symptoms or no
symptoms at all (Zeid et al., 2020).
Currently, GD1 is managed through intravenous enzyme replacement therapy (ERT) or
substrate reduction therapy (SRT). ERT provides a recombinant enzyme to overcome the
digestive block in the lysosomes. SRT is an oral treatment that aims to decrease the production
of glucocerebroside, allowing for the patient’s residual enzyme to be able to adequately break
down the remaining substrate. Individuals who do not receive regular ERT or SRT may
experience complications that necessitate splenectomies, blood transfusions, and joint
replacement surgeries (Biegstraaten et al., 2016). In general, these therapies are extremely
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effective, though costly, an approximate $200,000 annually in the United States per patient
(Zuckerman et al., 2007).
Pompe disease is a rare, often fatal, autosomal recessive condition also referred to as
Glycogen Storage Disease Type II (GSD II) (Cupler et al., 2012). It is caused by two pathogenic
variants in the GAA gene which causes a deficiency of acid alpha-glucosidase enzyme and a
buildup of glycogen in the cell (Lin et al., 2017). Pompe disease symptoms include progressive
muscle weakness and respiratory insufficiency (Cupler et al., 2012). This disease presents in two
forms, infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD), generally
distinguished by age of onset and the involvement of cardiomyopathy – a common cause of
death within the first year of life for IOPD patients (Lin et al., 2017).
Pompe disease is part of the Recommended Uniform Screening Panel (RUSP) list as one
of the conditions that the Secretary of the Department of Health and Human Services
recommends states include in newborn screening programs (NBS). Pompe disease can be
diagnosed through molecular genetic testing or measurement of residual acid alpha-glucosidase
enzyme activity. Molecular genetic testing is preferred; however, enzyme testing might be
helpful for testing asymptomatic individuals who have been diagnosed through ECS (Winchester
et al., 2008). In the United States, the frequency of Pompe disease is approximately 1 in 40,000.
However, studies from Israel, Taiwan, and NBS in some regions of the United States report
higher frequencies such as 1 in 25,000 in California. This NBS study also showed that the
frequency of IOPD (approximately 1 in 250,000) was much lower than the frequency of potential
LOPD (approximately 1 in 37,500) (Tang et al., 2020).
Enzyme replacement therapy can increase quality of life and slow progression of the
disease. Treatment of LOPD also involves physical and respiratory therapy to increase muscle
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and lung strength. ERT is an established treatment option during pregnancy and should be
considered (Koyunca et al., 2017). Long-term effects of treatment have not yet been studied, but
in general, patients are susceptible to premature death usually due to the effects of respiratory
muscle weakness (Winchester et al., 2008).
Fabry disease is a rare X-linked condition caused by a pathogenic variant in the GLA
gene that results in accumulation of globotriaosylceramide in lysosomes, due to reduced activity
of the enzyme alpha-galactosidase A (Biegstraaten et al., 2016). Classical Fabry disease presents
as a multisystem disease which usually begins to show in childhood or adolescence and causes
crises of burning pain in the hands and feet (acroparesthesia), angiokeratomas, sweating
abnormalities, kidney disease, cataracts and other eye issues. Classical and non-classical Fabry
disease are differentiated by percent of enzyme activity. Heterozygous females typically develop
milder symptoms with a later age of onset than males, but some have symptoms as severe as
affected males due to skewed X-inactivation and other unidentified mechanisms (Germain,
2010).
Fabry disease can be diagnosed through identifying alpha-galactosidase A enzyme
deficiency in males, although this testing is not diagnostic in females. Diagnosis can be made or
confirmed through molecular genetic testing and identification of a hemizygous GLA pathogenic
variant in males and a heterozygous GLA pathogenic variant in females (Biegstraaten et al.,
2016). Reported incidences in the general population range from 1 in 476,000 to 1 in 117,000.
These numbers may underestimate the true prevalence though, as NBS studies have shown much
higher incidences such as 1 in ~3,100 in Italy and 1 in 1,500 in Taiwan (Spada et al., 2006; Lin et
al., 2009).
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Fabry disease is managed by using a team of specialists to treat symptoms as they arise
and to regulate pain management. Experts recommend that enzyme replacement therapy be used
although long-term use has not been proven to continuously help manage symptoms
(Biegstraaten et al., 2016). In heterozygous females, life threatening manifestations have been
seen including cardiac ischemia, cerebrovascular accidents, hypertension, dysrhythmias, and
renal insufficiency (Wang et al., 2007). Death from Fabry disease usually occurs from
complications of renal disease, cardiac disease, and cerebrovascular disease.
Incidental diagnosis on carrier screening of patients without prior symptoms of a lateonset disease presents challenges in determining ongoing surveillance and when to consider
initiation of treatment. It also presents psychosocial challenges for the patient faced with an
unexpected diagnosis, particularly during pregnancy. With the exception of select case reports,
this phenomenon of incidental diagnosis is not yet studied in the area of late-onset genetic
conditions on ECS, and thus there is much to be learned regarding the impact of this event on
patients, conduction of medical surveillance and treatment decisions, and on the wider healthcare
system. Qualitative study of the patient experience in this scenario has not yet been completed,
presenting a novel opportunity. This study aims to provide qualitative insight on the patient
experience so that relevant providers in this area may gain valuable knowledge for their practice,
and to bring attention to this phenomenon.

Methods
Participants
A total of 12 patients receiving care at the New York University Lysosomal Storage
Disorders Program who received an incidental diagnosis of a late-onset lysosomal storage
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disorder on preconception or prenatal expanded carrier screening met criteria for participation.
These individuals included 3 males and 8 females who ranged in age from 25 to 39 years. One
patient was excluded because they discontinued care at this facility. The sub-investigator
contacted the remainder of the patients about participation in the study, four of whom indicated
interest, completed and returned consent forms, and engaged in structured interviews with study
staff. IRB approval was obtained from the NYU School of Medicine.

Materials
This study consists of a one page quality of life scale (QoLS) questionnaire and a guided
interview by audio call. The recordings were transcribed and sent back to the participants for
review. The questions included in the interviews elicited responses for three periods in the
patient’s experience with incidental diagnosis: initial experience with ECS, the period directly
after incidental diagnosis, and the current period after they established care with a specialty
clinic in regards to their diagnosis.

Procedure
Participants were recruited from the clinical practice of the principal investigator and the
sub-investigator. Participants were identified by Epic data review of new patients seen in the
clinical practice between September 1st, 2015 and October 1, 2019, diagnosed with a late-onset
LSD. Recruitment took place over the phone and email where an electronic copy of the consent
forms, QoLS, and available time slots for the audio interview were emailed to the participant.
The interview portion of the study took place by audio call on the web conference platform Cisco
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WebEx by a study staff member located in a private remote location. Participants completed a
structured interview regarding their experience of diagnosis and access to medical care.
The PI and the sub-I had access to Epic data for clinical care and the following data
points and Protected Health Information (PHI) from Epic were used for research: Name, phone
number, and email were used for study recruitment and communication, and LSD disease
diagnosis, gender, and age (documented as a 5 year age range e.g. 20-24 years) were used for
analysis.
This study conducted preliminary qualitative data analysis. Analyses described individual
data by drawing on themes in participant responses and presenting limited quotes of direct
participant responses. Data was described according to type of participant diagnosis, time period
since receiving the diagnosis, whether patient received pretest counseling about incidental
diagnoses, and whether the diagnosis was received in the context of prenatal or preconception
care, but these groups were not expected to achieve statistical significance in light of the small
study size. Answers to QoLS questions were summarized quantitatively using average scores for
each participant, average scores across each question and range among scores for each question.
Trends among participant satisfaction scores were evaluated qualitatively.

Results
Four interviews were conducted with female participants who have been incidentally
diagnosed with Gaucher Disease Type 1, Late-onset Pompe Disease and Fabry Disease. Three
participants received ECS for preconception purposes, and one received ECS prenatally.
Interviews lasted between 25-45 minutes.
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Six main categories emerged from the participants’ responses: 1) quality of explanation
of ECS prior to testing, 2) quality of health education during results disclosure, 3) emotional
response to first knowledge of incidental diagnosis, 4) impact of diagnosis on quality of life, 5)
impact of specialized care on experience with diagnosis, and 6) current attitude about ECS.
Themes from each category are elucidated below, as well as main trends from patient
responses to the Quality of Life Surveys (QoLS). QoLS responses and participants’ demographic
information are summarized in Tables I and II, respectively.

Explanation of ECS prior to testing
A common theme among participant responses was that the participants recalled not
receiving significant education on the specifics of ECS, for example the conditions that would be
included in the testing panel and the types of results that can return. None of them remember
having received formal pre-test counseling. Much of the participants’ knowledge of ECS prior to
testing was reportedly from their past experiences; they had either heard of other people in their
community who underwent a similar type of test, or they heard about genetic screening through
word-of-mouth. All participants expressed that they never expected to receive a positive result,
especially one that indicated that they were diagnosed with a genetic condition themselves. One
participant stated that there were some educational materials that were included with her directto-consumer testing kit, but that she did not read them carefully. She remembered thinking that
the testing process was simple and knowing some details about the test beforehand, such as
variation in severity of conditions covered, because many people in her community undergo
ECS. Both participants who received ECS during their appointment at fertility clinics stated that
they had no choice about genetic testing as they recall it was presented as a mandatory procedure
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during their evaluation. One of these participants said that she did not know that a genetic test
had been ordered for her, although she reported that she was not in a place to pay attention to any
information about ECS due to impatience to initiate the in vitro fertilization process. Several
participants stated that they received their results in a stepwise process; for example, an initial
email disclosing the results followed by a phone call, or an initial email followed by an in-person
appointment to discuss the results.

Quality of health education during results disclosure
All participants received their ECS results either through their ordering physician, a
genetic counselor, or a combination of both. Regardless of the type of provider that disclosed the
results, their perceived level of knowledge about the incidentally diagnosed condition heavily
influenced participants’ satisfaction with their explanation. The participants were concerned with
several aspects of their diagnosis: the clinical features of the disorder itself, how it would impact
them, and resources for dealing with the diagnosis. Participants were dissatisfied with providers
who they felt were not knowledgeable about the diagnosis and who could not provide details
about prognosis and treatment. According to several participants, their providers admitted that
they knew little about the genetic condition that was diagnosed. Participants were also
dissatisfied when they felt a lack of ability to provide referrals to specialty clinics or to resources
that could help them manage their diagnosis. Several participants said that they were left to their
own devices in regards to finding follow-up care, and they either turned to the internet or their
insurance company to look for specialty providers. Participants also reported utilizing the
internet to find more information about their genetic condition, which often led to increased
anxiety when they learned about serious or life-threatening symptoms. Participant 1 stated that
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she was satisfied with her results disclosure and that it was straightforward for her to initiate next
steps in her care because she recalled being given a thorough explanation of her genetic
condition and a referral to an appropriate specialty clinic.

Feelings upon initial news of incidental diagnosis
All participants recalled feeling surprised at their incidental diagnosis. Participant 2 said
“I was upset, I was disappointed, I was concerned, I was confused, I was worried” upon hearing
her results. Two participants expressed a degree of denial about their results due to their absence
of symptoms. Participant 3 reported hoping that she was misdiagnosed, and Participant 1
reported having to take some time before the reality of her diagnosis could sink in. Several
participants expressed a level of confusion that did not resolve after speaking with their
diagnosing provider, because they still felt anxious after their providers’ explanations. One
participant said that she felt afraid because she thought that she could develop symptoms at any
moment or die at a much younger age than she had expected.

Impact of diagnosis on quality of life
The degree to which each participant felt that their diagnosis affected their everyday lives
depended mostly on the nature of follow-up activities and their plans regarding pregnancy. One
participant stated that her diagnosis did not significantly affect her quality of life until she began
to undergo enzyme replacement therapy. She cites difficulty with time management, financial
challenges and juggling of multiple responsibilities as factors that decrease her quality of life.
Several participants, including one who was asymptomatic, said that getting insurance coverage
for their condition is a major concern, both in terms of paying for treatment and of being able to
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get supplemental insurance coverage with a pre-existing condition. Both participants 1 and 4
report experiencing difficulty with getting their treatments covered under their health insurance
plans. Participant 3 said that her diagnosis compelled her to purchase life and disability
insurance--something she had been delaying--in case she needed it in the future. She said that she
expected pushback from the insurance company due to having a known genetic condition, and
was pleasantly surprised that she was able to purchase the insurance that she wanted. The
participants who are currently asymptomatic stated that their diagnosis does not significantly
influence their everyday activities and relationships. However, they reported feeling anxiety and
uncertainty about the future since it is difficult to predict when, if ever, symptoms would appear.
One participant who was diagnosed while pregnant said that she became more cautious
about her pregnancy and elicited extra professional help for the birthing process that she would
not have done otherwise. She also reported needing to follow up with different specialists due to
the fact that pregnancy increases the risk of symptoms. Both participants who were diagnosed
while undergoing or preparing to undergo fertility procedures said that their treatment was
delayed or complicated by their diagnosis. Participant 2 said that could not continue until she had
received medical clearance from a specialist for her condition, and participant 4 stated that she
underwent a second round of preimplantation genetic testing before proceeding with her
pregnancy, which increased her treatment costs.
A positive effect that stemmed from incidental diagnoses in this cohort was that several
of the participants’ relatives received diagnoses themselves through cascade testing, some of
whom are currently receiving treatment for significant symptoms. One participant’s brother was
reported to have symptoms all his life that did not lead to a diagnosis until the participant
underwent ECS and identified the probable cause. That participant stated that her incidental
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diagnosis improved her relationship with her brother because she now has greater concern for his
health.

Impact of specialized care on diagnosis
All participants indicated that having access to a doctor who specializes in the rare
diseases with which they were diagnosed was helpful. The participants who were dissatisfied
with the initial explanation of their results remembered feeling less anxious and more informed
after they met with a specialist who was familiar with their condition. One participant said that
the doctor was the resource she would depend on the most should she develop symptoms of her
condition. All participants appreciated thorough explanation of the treatment options available,
and one person said that she liked the doctor’s dedication to research because it made her hopeful
for better treatment in the future. Multiple participants felt that their needs were being heard and
addressed by the doctor, which was important to them.
Participants mentioned a few other resources that were helpful to them, including a
patient advocacy group dedicated to their genetic condition, a case manager at the
pharmaceutical company prescribing enzyme replacement therapy, and the internet at large.
Participant 3 said that she was only able to find a specialist after contacting a support line at a
patient advocacy website dedicated to Pompe disease. She stated that advocates working for this
group also connected her to other people with the same diagnosis and informed her of
community events and resources. Participant 1 said her case manager was her most helpful
resource because she supports her emotionally and helps coordinate her treatments. Several
participants turned to the internet for information regarding their diagnosis, which was not
always a successful strategy. However, one participant said that she was able to get most of the
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information needed online, which was crucial because she felt that the provider who disclosed
the results to her did not provide enough explanation.

Current attitude about ECS
All participants reported that they would undergo ECS again if they had the choice,
because they believed that expanded carrier screening gave important information. Several
participants stated that ECS should be offered to everyone. Participant 1 added that she
recommends individuals pursue carrier screening that includes a comprehensive list of
conditions, because she knew of carrier screening options that would not have included the
condition with which she was diagnosed. All participants advised providers disclosing ECS
results to be knowledgeable about the conditions in which they are educating their patients, and
be prepared to provide resources, such as pamphlets or referrals to patient groups. One
participant also expressed a desire for the provider to demonstrate compassion during results
disclosure. One participant remarked that it would be helpful for providers to recommend ECS to
women who are considering getting pregnant as carrier screening has the most impact for
reproductive decision making during the preconception period. She also advised providers to
educate individuals undergoing ECS on the possibility of incidental diagnosis, as she did not
recall being educated about this possibility prior to testing.
Despite the confusion and difficulty that sometimes accompanied their experiences
surrounding incidental diagnosis, several participants stated that they appreciated ECS for giving
information that was useful not only for pregnancy, but for personal health purposes as well. One
participant stated that she “would rather [have known] about it now than not know about it”.

22

QoLS answers
The QoLS consists of 16 questions to which participants scored a number from 1-7, 1
indicating the lowest satisfaction with the area of life assessed by the question and 7 indicating
the highest. Each participant’s scores were averaged across all questions; the average score
among participants for each question was calculated as well as the range among participant
scores for each question. Among the three participants who returned their surveys, their average
reported scores were 5.9, 5.5 and 5.5 across all questions, between mostly satisfied (a score of 5)
and pleased (a score of 6). No participants scored lower than 4 (mixed) to any question. The
questions that elicited the lowest average scores among all participants were numbers 8, 10, 12
and 15 (average scores of 4.33, 5, 5 and 5 respectively). These questions asked about
participating in organizations/public affairs, understanding the self, expressing the self
creatively, and participating in active recreation. Notably, there was no range in participant
responses for questions number 10 and 12 (self-understanding and self-expression). The
questions that elicited the highest average scores among all participants were numbers 5 and 16
(average scores of 6.67 for both questions). These questions pertained to the participants’
satisfaction with relationships to spouses or significant others and level of independence. There
was a range of 1 for both responses among participants’ scores. Other questions that featured
high average scores among all participants were numbers 1, 3, and 6 (all scores of 6.33), which
asked about material comforts, family relationships and relationships with close friends,
respectively. There was a range of 1 in the responses for each of these questions. Responses to 6
out of 16 questions had a range of 2, and responses to 1 out of 16 questions had a range of 3. The
questions that had greater range in response tended to ask about day-to-day activities, such as
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working, studying, or doing leisure activities. Having and rearing children also elicited a range of
2.
Overall, participant satisfaction with the categories mentioned on the questionnaire are
moderate to high, with more variation (score range of 2-3) in responses to the categories that
depend on individual circumstances, such as work, time and/or resources with which to do
leisurely, civic or educational activities, and having or raising children. Participants reported the
highest levels of satisfaction with their independence, material comfort, and close relationships,
and there was low discrepancy in the participants’ ratings of these categories (score range of 01). No participants rated themselves as actively dissatisfied with any category of life elicited by
the questionnaire. The participants had different experiences in terms of pregnancy, but all of
them reported that they were “mostly satisfied” to “delighted” in terms of having children and
childcare. The participants reported that they were “mostly satisfied” or “pleased” with their
health, including the ones who were exhibiting symptoms and undergoing treatment at the time
of the interview.

Table I. QoLS Answers
scale is designated as follows: 7-Delighted; 6-Pleased; 5-Mostly satisfied; 4-Mixed; 3-Mostly
dissatisfied; 2-Unhappy; 1-Terrible
Category

Participant
1 scores

Participant
2 scores*

Participant
3 scores

Participant
4 scores

Average
score for
question

Range

1. Material
comforts
home, food,
conveniences,
financial
security

7

-

6

6

6.33

1

2. Health being

6

-

6

5

5.67

1
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physically fit
and vigorous
3.
7
Relationships
with parents,
siblings &
other relativescommunicatin
g, visiting,
helping

-

6

6

6.33

1

4. Having and
rearing
children

6

-

5

7

6

2

5. Close
relationships
with spouse or
significant
others

7

-

6

7

6.67

1

6. Close
friends

6

-

6

7

6.33

1

7. Helping and
encouraging
others,
volunteering,
giving advice

5

-

5

7

5.67

2

8. Participating 4
in
organizations
and public
affairs

-

5

4

4.33

1

9. Learningattending
school,
improving
understanding,
getting
additional
knowledge

-

4

5

5

2

6
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10.
Understanding
yourself knowing your
assets and
limitations knowing what
life is about

5

-

5

5

5

0

11. Work - job
or in home

7

-

5

5

5.67

2

12. Expressing
yourself
creatively

5

-

5

5

5

0

13. Socializing 6
- meeting other
people, doing
things, parties,
etc

-

6

4

5.33

2

14. Reading,
listening to
music, or
observing
entertainment

7

-

5

4

5.33

3

15.
Participating
in active
recreation

5

-

6

4

5

2

16.
Independence,
doing for
yourself

6

-

7

7

6.67

1

Participant’s
average score

5.9

-

5.5

5.5

-

-

ECS ordered
by

Diagnosis

*Participant 2 did not return her QOLS to the study team.
Table II. Participant demographics
Participant
number

Age at time
of diagnosis

Time since
incidental

Method of
results
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(years,
diagnosis
presented as a
5 year range)

disclosure/pro
vider type

1

25-29

2.5 years

Self, through Gaucher
direct-toDisease Type
consumer site 1

Email, then
over the
phone with a
genetic
counselor

2

35-39

6 months

Fertility
doctor

Gaucher
Disease Type
1

In person,
physician

3

35-39

4 years

OBGYN

Late-Onset
Pompe
Disease

In person,
physician and
genetic
counselor

4

30-34

4 months

Fertility
doctor

Non-classical
Fabry
Disease

Email, then in
person with a
physician

Discussion
The advent of expanded carrier screening over 10 years ago has made determining
reproductive risk for individuals and couples more widespread. In this study, we assessed the
psychological outcomes of receiving an incidental diagnosis from ECS. Until this study,
qualitative insight on the patient experience of receiving an incidental diagnosis from ECS had
not yet been investigated.

Practice implications
Ensuring adequate pre-test counseling is an important process for any type of genetic
testing, especially ECS because of the extensive number of diseases it may entail. The informed
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consent process should address the results a patient may receive, including incidental diagnosis
(Janssens et al., 2017). Perceived lack of quality informed consent was highlighted in our study
by the patients’ confusion upon receiving a diagnosis, especially in the absence of any prior
symptoms. The subjects in this study valued the information given to them through ECS. They
reported emotional distress from the time they were first disclosed the results until they were
able to speak with a LSD specialist. Adequate pre-test counseling may have better prepared them
psychologically for this type of result by preparing them for the unexpected. We recommend that
providers offering ECS discuss incidental diagnoses as part of the informed consent process.
A common theme noted in this pilot study was that individuals were more satisfied when
they received additional support and resources. The level of knowledge of the provider who
disclosed results to the patients heavily influenced initial patient satisfaction, with greater
knowledge resulting in higher satisfaction. Without satisfactory knowledge from their provider,
many individuals used the internet as their primary resource for information. This leaves the
potential for emotional distress and misinformation. Adequate counseling and information about
a diagnosis could prevent patients from relying on online sources for medical information.
Specifically, patients requested details about the impact of the disease, resources for dealing with
the diagnosis, and details about prognosis and treatment. Patient’s found that patient advocacy
groups, a case manager from the pharmaceutical company providing enzyme replacement
therapy, insurance companies, labs, and the internet at large served as resources when there was
insufficient information given by their provider. We suggest that clinics that offer ECS also offer
resources such as pamphlets of information for late-onset diseases commonly found in ECS,
medical counseling by professionals familiar with the specific disease, such as referral to a
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genetic counselor, and have a plan in place to refer out to specialists in the area who treat and
manage these conditions.
All subjects interviewed reported that they did not experience symptoms prior to their
diagnosis. Some patients with LSDs may be asymptomatic or mildly symptomatic throughout
their lifetime which can complicate patient education, reproductive risk, and adult health
management (Lazarin et al., 2013). Patients in this study expressed feelings of denial and
uncertainty about their future health. In the absence of symptoms and without adequate
information initially given, it was difficult for patients to understand their disease and how it
would affect their finances, personal lives, and time management. This highlights that incidental
diagnoses are difficult for patients to adjust to, which providers should take into consideration if
encountered in their practice. After meeting with an LSD specialist, the same patients reported
feeling more capable and equipped to handle their diagnosis. Without adequate medical
counseling prior to and after testing, ECS may cause unnecessary anxiety for patients.
Despite the issues experienced by the participants in this study, the subjects reported that
they would have testing again if offered and that they would recommend testing to others in their
community. The patient’s expressed that the knowledge gained through ECS was useful
information for their personal health, their reproductive health, and their families. We suggest
that providers who offer ECS ensure that their clinics offer satisfactory pre-test counseling,
ample resources for information on late-onset conditions, and be prepared to refer patients to
specialists for their disease, particularly those with a high frequency in founder populations, such
as Gaucher Type 1 in the Ashkenazi Jewish population, or non-classical Fabry disease in the
Taiwanese population.
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Study limitations
One limitation of this study is the small sample size (N=4). One way that this could be
addressed is to recruit individuals from multiple LSD clinics. Patients should be recruited from
multiple ethnic backgrounds and countries when possible in order to discern differences in the
experiences of individuals that have arrived at their incidental diagnoses who have alternative
ethnic, socioeconomic and cultural backgrounds than those represented in this study sample. It
would also be helpful to know if differences in accessibility and quality of healthcare in different
parts of the US and the world affect individuals’ outlook on incidental diagnoses. In addition to
eliciting recruitment from other LSD centers, patients could be recruited from centers that see
patients who have been incidentally diagnosed with additional late-onset or low-penetrance
diseases commonly placed on ECS panels.
Secondly, although we utilized the QoLS to assess the psychosocial experience of the
participants numerically, it is difficult to correlate their answers on the survey to the outcomes
that they spoke about related to incidental diagnosis. It is possible that some question categories
are significantly related to the participants’ experience of incidental diagnoses while other
categories are not at all related. The scores could be affected by other life factors that this study
does not address, as well as individual characteristics affecting mood, outlook on the future,
resilience and adaptation. Because there are no QoLS responses taken in the peri-diagnostic
period with which to compare the current QoLS assessments, it is also difficult to determine
whether participants’ satisfaction with life has changed in the intervening time using this
quantitative method.
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Research recommendations
In future studies, it would be valuable to include a control group of adult patients that
have been diagnosed with late-onset LSDs based on symptoms and compare their diagnosis
experience with that of individuals diagnosed from ECS. Another avenue for future research
would be to ask whether or not the patient’s partner was tested. There were varying degrees of
anxiety surrounding future pregnancies for the patients. It would be valuable to know whether or
not their knowledge about the risk of their children having this disease was the cause for this
concern or lack of concern.
If including QoLS in future studies, it would be helpful to ask participants specifically
about the effect of their incidental diagnosis on any areas of the questionnaire that have
particularly high or low scores so as to determine how the scoring relates specifically to the
patient’s experience of incidental diagnosis. If the QoLS is not incorporated, it may be helpful to
add additional detail to the interview script eliciting categories such as childcare, ability to
participate in public and private activities, and material comfort in order to elicit how satisfaction
in these categories has changed over time.
This pilot study provides initial insight into the importance of pre- and post-test
counseling for ECS. Satisfactory pre-test counseling for ECS should include a clear discussion of
the possibility of incidental diagnosis of late-onset conditions. Disclosing the diagnosis should be
accompanied by ample support, information, and resources. Likewise, post-test counseling
should resolve uncertainty and anxiety by supplementing the patient with resources and referrals
to specialists for their condition. The growing use of ECS will bring about more incidental
diagnoses and the importance of satisfactory pre- and post-test counseling must be implemented
for the psychosocial and personal health benefit of the patient.
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